Astellas Pharma (ALPMY)
(Delayed Data from OTC)
$12.16 USD
+0.07 (0.55%)
Updated Sep 23, 2024 01:30 PM ET
2-Buy of 5 2
B Value C Growth B Momentum A VGM
Income Statements
Fiscal Year end for Astellas Pharma Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 10,620 | 11,418 | 10,624 | 11,257 | 11,934 |
Cost Of Goods | 1,937 | 2,168 | 2,074 | 2,217 | 2,539 |
Gross Profit | 8,683 | 9,250 | 8,550 | 9,040 | 9,395 |
Selling & Adminstrative & Depr. & Amort Expenses | 8,513 | 8,250 | 7,274 | 7,814 | 7,156 |
Income After Depreciation & Amortization | 170 | 1,000 | 1,276 | 1,226 | 2,239 |
Non-Operating Income | 76 | 61 | 50 | 105 | 40 |
Interest Expense | 80 | 66 | 41 | 21 | 28 |
Pretax Income | 165 | 995 | 1,286 | 1,309 | 2,251 |
Income Taxes | 52 | 253 | 269 | 223 | 458 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 113 | 742 | 1,017 | 1,086 | 1,793 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 113 | 742 | 1,017 | 1,086 | 1,793 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 1,215 | 1,795 | 1,929 | 1,881 | 2,848 |
Depreciation & Amortization (Cash Flow) | 1,045 | 795 | 653 | 655 | 609 |
Income After Depreciation & Amortization | 170 | 1,000 | 1,276 | 1,226 | 2,239 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 1,799.89 | 1,825.06 | 1,850.60 | 1,857.22 | 1,877.51 |
Diluted EPS Before Non-Recurring Items | 0.58 | 0.91 | 0.60 | 0.61 | 0.96 |
Diluted Net EPS (GAAP) | 0.06 | 0.41 | 0.55 | 0.58 | 0.95 |
Fiscal Year end for Astellas Pharma Inc falls in the month of March .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 3,027.99 | 2,793.59 | 2,857.32 | 2,714.06 | 2,737.43 |
Cost Of Goods | 583.27 | NA | NA | NA | 503.31 |
Gross Profit | 2,444.72 | NA | NA | NA | 2,234.11 |
SG&A, R&D, and Dept/Amort Expenses | 2,120.52 | 0.00 | 0.00 | 0.00 | 1,899.81 |
Income After SG&A, R&D, and Dept/Amort Expenses | 324.20 | 0.00 | 0.00 | 0.00 | 334.30 |
Non-Operating Income | 27.73 | NA | NA | NA | 27.56 |
Interest Expense | 28.77 | NA | NA | NA | 19.86 |
Pretax Income | 323.17 | NA | NA | NA | 342.01 |
Income Taxes | 82.51 | NA | NA | NA | 100.16 |
Minority Interest | 0.00 | NA | NA | NA | 0.00 |
Investment Gains/Losses | 0.00 | NA | NA | NA | 0.00 |
Other Income/Charges | 0.00 | NA | NA | NA | 0.00 |
Income From Cont. Operations | 240.66 | -224.23 | 126.32 | -10.10 | 241.84 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 240.66 | -224.23 | 126.32 | -10.10 | 241.84 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1,790.62 | 1,799.78 | 1,800.48 | 1,823.75 | 1,794.64 |
Diluted EPS Before Non-Recurring Items | 0.24 | 0.11 | 0.12 | -0.01 | 0.13 |
Diluted Net EPS (GAAP) | 0.13 | -0.12 | 0.07 | -0.01 | 0.13 |